ライブ
FierceBiotechWhy Execution Excellence Now Defines Biopharma WinnersFierceBiotechHow integrated strategy is reshaping biopharma growthFierceBiotechBiotech value creation at an inflection pointFierceBiotechGSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regressionPharmaVoice3 potential takeover targets in obesityFierceBiotechHow Unlearn is building a scientific intelligence layer for clinical developmentFierceBiotechHow AI is reshaping biopharma decision-makingFierceBiotechBiopharma IPOs: Timing, capital and staying flexibleRoche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical TechnologyEndpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealEndpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealEndpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3B
Endpoints News 2025年12月22日

Shionogi will pay $2.5B to acquire one of the only approved ALS drugs

Shionogi will pay $2.5B to acquire one of the only approved ALS drugs

原文
本文は利用できません。元の情報源をご確認ください。